Floatz logo

Venetoclax

Elderly Patients (60-75 Years)

Shanghai General Hospital, Shanghai Jiao Tong University School of MedicineSmall moleculePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
45/ 100
Competitive Position
95/ 100

Competitive context

2 Active assets in the Elderly Patients (60-75 Years) cohort.

Asset / SponsorPhaseRating
Azacitidine
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3B
Omacetaxine
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 3B

Same molecule, other indications

Venetoclax is also rated in:

Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 PositiveDormant
BBB
Indicative ·
72 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
myeloid neoplasmDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →